Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
Although SARS-CoV-2 is considered a lung-tropic virus, severe COVID-19 is not just a viral pulmonary infection, clinically it is a multi-organ pathology with major coagulation abnormalities and thromboembolism events. Recently, antiphospholipid (aPL) antibodies were found increased in a large number...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-02-01
|
Series: | Journal of Microbiology, Immunology and Infection |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1684118221000074 |
id |
doaj-f693e898d2034f26a98b91d76112855e |
---|---|
record_format |
Article |
spelling |
doaj-f693e898d2034f26a98b91d76112855e2021-02-21T04:32:02ZengElsevierJournal of Microbiology, Immunology and Infection1684-11822021-02-015413745Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?Christian A. Devaux0Laurence Camoin-Jau1Jean-Louis Mege2Didier Raoult3Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France; CNRS, Marseille, France; Corresponding author. IHU Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13385, Marseille, France. Fax: +33 4 13 73 20 52.Aix-Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France; Laboratoire D'Hématologie, Hôpital de La Timone, APHM, Boulevard Jean- Moulin, 13005, Marseille, FranceAix-Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, FranceAix-Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, FranceAlthough SARS-CoV-2 is considered a lung-tropic virus, severe COVID-19 is not just a viral pulmonary infection, clinically it is a multi-organ pathology with major coagulation abnormalities and thromboembolism events. Recently, antiphospholipid (aPL) antibodies were found increased in a large number of COVID-19 patients. Elevated aPL have been well documented in antiphospholipid syndrome (APS), a systemic autoimmune disorder characterized by recurrent venous or arterial thrombosis and/or obstetrical morbidity. Among treatment regimen of APS, hydroxychloroquine (HCQ) is one of the molecules proposed in the primary prevention of thrombosis and obstetrical morbidity in those patients. Due to its antithrombotic properties documented in APS therapy, HCQ could be considered a good candidate for the prevention of thrombotic events in COVID-19 patients in association with anticoagulant and its repurposing deserves further evaluation.http://www.sciencedirect.com/science/article/pii/S1684118221000074COVID-19ThrombosisAntiphospholipid antibodiesHydroxychloroquine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christian A. Devaux Laurence Camoin-Jau Jean-Louis Mege Didier Raoult |
spellingShingle |
Christian A. Devaux Laurence Camoin-Jau Jean-Louis Mege Didier Raoult Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ? Journal of Microbiology, Immunology and Infection COVID-19 Thrombosis Antiphospholipid antibodies Hydroxychloroquine |
author_facet |
Christian A. Devaux Laurence Camoin-Jau Jean-Louis Mege Didier Raoult |
author_sort |
Christian A. Devaux |
title |
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ? |
title_short |
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ? |
title_full |
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ? |
title_fullStr |
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ? |
title_full_unstemmed |
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ? |
title_sort |
can hydroxychloroquine be protective against covid-19-associated thrombotic events ? |
publisher |
Elsevier |
series |
Journal of Microbiology, Immunology and Infection |
issn |
1684-1182 |
publishDate |
2021-02-01 |
description |
Although SARS-CoV-2 is considered a lung-tropic virus, severe COVID-19 is not just a viral pulmonary infection, clinically it is a multi-organ pathology with major coagulation abnormalities and thromboembolism events. Recently, antiphospholipid (aPL) antibodies were found increased in a large number of COVID-19 patients. Elevated aPL have been well documented in antiphospholipid syndrome (APS), a systemic autoimmune disorder characterized by recurrent venous or arterial thrombosis and/or obstetrical morbidity. Among treatment regimen of APS, hydroxychloroquine (HCQ) is one of the molecules proposed in the primary prevention of thrombosis and obstetrical morbidity in those patients. Due to its antithrombotic properties documented in APS therapy, HCQ could be considered a good candidate for the prevention of thrombotic events in COVID-19 patients in association with anticoagulant and its repurposing deserves further evaluation. |
topic |
COVID-19 Thrombosis Antiphospholipid antibodies Hydroxychloroquine |
url |
http://www.sciencedirect.com/science/article/pii/S1684118221000074 |
work_keys_str_mv |
AT christianadevaux canhydroxychloroquinebeprotectiveagainstcovid19associatedthromboticevents AT laurencecamoinjau canhydroxychloroquinebeprotectiveagainstcovid19associatedthromboticevents AT jeanlouismege canhydroxychloroquinebeprotectiveagainstcovid19associatedthromboticevents AT didierraoult canhydroxychloroquinebeprotectiveagainstcovid19associatedthromboticevents |
_version_ |
1724258814277976064 |